161 related articles for article (PubMed ID: 31679112)
1. Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.
Wick W; Krendyukov A; Junge K; Höger T; Fricke H
J Neurooncol; 2019 Dec; 145(3):531-540. PubMed ID: 31679112
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
[TBL] [Abstract][Full Text] [Related]
3. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wick W; Fricke H; Junge K; Kobyakov G; Martens T; Heese O; Wiestler B; Schliesser MG; von Deimling A; Pichler J; Vetlova E; Harting I; Debus J; Hartmann C; Kunz C; Platten M; Bendszus M; Combs SE
Clin Cancer Res; 2014 Dec; 20(24):6304-13. PubMed ID: 25338498
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Wei KC; Hsu PW; Tsai HC; Lin YJ; Chen KT; Toh CH; Huang HL; Jung SM; Tseng CK; Ke YX
Sci Rep; 2021 Dec; 11(1):24067. PubMed ID: 34911992
[TBL] [Abstract][Full Text] [Related]
5. EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy.
Caissie A; Culleton S; Nguyen J; Zhang L; Zeng L; Holden L; Dennis K; Chan E; Jon F; Tsao M; Danjoux C; Sahgal A; Barnes E; Koo K; Chow E
Support Care Cancer; 2012 Apr; 20(4):841-8. PubMed ID: 21538099
[TBL] [Abstract][Full Text] [Related]
6. The EORTC QLQ-BN20 for assessment of quality of life in patients receiving treatment or prophylaxis for brain metastases: a literature review.
Leung A; Lien K; Zeng L; Nguyen J; Caissie A; Culleton S; Holden L; Chow E
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):693-700. PubMed ID: 22098285
[TBL] [Abstract][Full Text] [Related]
7. Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma.
Scartoni D; Amelio D; Palumbo P; Giacomelli I; Amichetti M
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1615-1622. PubMed ID: 32200460
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
9. Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases.
Wong E; Zhang L; Kerba M; Arnalot PF; Danielson B; Tsao M; Bedard G; Thavarajah N; Cheon P; Danjoux C; Pulenzas N; Chow E
Support Care Cancer; 2015 Sep; 23(9):2731-7. PubMed ID: 25663577
[TBL] [Abstract][Full Text] [Related]
10. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy.
Raman S; Ding K; Chow E; Meyer RM; Nabid A; Chabot P; Coulombe G; Ahmed S; Kuk J; Dar AR; Mahmud A; Fairchild A; Wilson CF; Wu JSY; Dennis K; DeAngelis C; Wong RKS; Zhu L; Brundage M
Qual Life Res; 2016 Oct; 25(10):2535-2541. PubMed ID: 27138964
[TBL] [Abstract][Full Text] [Related]
11. Fatigue scores in patients with brain metastases receiving whole brain radiotherapy.
Pulenzas N; Khan L; Tsao M; Zhang L; Lechner B; Thavarajah N; Barnes E; Danjoux C; Holden L; Lauzon N; Sheehan P; Bedard G; Chow E
Support Care Cancer; 2014 Jul; 22(7):1757-63. PubMed ID: 24510194
[TBL] [Abstract][Full Text] [Related]
12. Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/Progressive Glioma Treated with High-dose Salvage Re-irradiation.
Maitre P; Gupta T; Maitre M; Goda J; Krishnatry R; Chatterjee A; Sridhar E; Sahay A; Mokal S; Moiyadi A; Shetty P; Patil V; Jalali R
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e155-e165. PubMed ID: 32917486
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
[TBL] [Abstract][Full Text] [Related]
14. The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma.
Flechl B; Sax C; Ackerl M; Crevenna R; Woehrer A; Hainfellner J; Preusser M; Widhalm G; Kiesel B; Lütgendorf-Caucig C; Dieckmann K; Steffal C; Marosi C; Hassler MR
Radiother Oncol; 2017 Nov; 125(2):228-233. PubMed ID: 28801008
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.
Lam K; Zeng L; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Sahgal A; Poon M; Chow E
J Palliat Med; 2013 Apr; 16(4):402-8. PubMed ID: 23458649
[TBL] [Abstract][Full Text] [Related]
17. Impact of response shift on time to deterioration in quality of life scores in breast cancer patients.
Hamidou Z; Dabakuyo-Yonli TS; Guillemin F; Conroy T; Velten M; Jolly D; Causeret S; Graesslin O; Gauthier M; Mercier M; Bonnetain F
PLoS One; 2014; 9(5):e96848. PubMed ID: 24828426
[TBL] [Abstract][Full Text] [Related]
18. Minimal important differences in the EORTC QLQ-C15-PAL to determine meaningful change in palliative advanced cancer patients.
Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Hicks K; Chow E
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e38-46. PubMed ID: 23551493
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life in a Hospice: A Validation of the Croatian Version of the EORTC QLQ-C15-PAL.
Golčić M; Dobrila-Dintinjana R; Golčić G; Pavlović-Ružić I; Stevanović A; Gović-Golčić L
Am J Hosp Palliat Care; 2018 Aug; 35(8):1085-1090. PubMed ID: 29466864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
